Marina S Syrkina - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Current Pharmaceutical Design|December 10, 2015

RGD-based Therapy: Principles of SelectivityMikhail A Rubtsov, Marina S Syrkina, Gjumrakch Aliev

Current Medicinal Chemistry|August 19, 2017

MUC1 Story: Great Expectations, Disappointments and the RenaissanceMarina S Syrkina, Yegor S Vassetzky, Mikhail A Rubtsov

Protein Engineering, Design & Selection : PEDS|November 20, 2012

Preparation and functional evaluation of RGD-modified streptavidin targeting to integrin-expressing melanoma cellsMarina S Syrkina, Dmitry A Shirokov, Mikhail A Rubtsov, et al.

Frontiers in Immunology|June 1, 2026

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity <i>in vitro</i>Yi-Ping Shih, Stephan Drokin, Olivia Burke, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Current Pharmaceutical Design|December 10, 2015

RGD-based Therapy: Principles of SelectivityMikhail A Rubtsov, Marina S Syrkina, Gjumrakch Aliev

Current Medicinal Chemistry|August 19, 2017

MUC1 Story: Great Expectations, Disappointments and the RenaissanceMarina S Syrkina, Yegor S Vassetzky, Mikhail A Rubtsov

Protein Engineering, Design & Selection : PEDS|November 20, 2012

Preparation and functional evaluation of RGD-modified streptavidin targeting to integrin-expressing melanoma cellsMarina S Syrkina, Dmitry A Shirokov, Mikhail A Rubtsov, et al.

Frontiers in Immunology|June 1, 2026

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity <i>in vitro</i>Yi-Ping Shih, Stephan Drokin, Olivia Burke, et al.

Pageof 1